Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Observation Unit
NCT03168529 · Phillip Levy · PHASE4 · terminated · last registry update 2026-09-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of patient enrollment” | – | Registry record, Phillip Levy |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HCN4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-21Results posted on the registry: Barts & The London NHS Trust, Medical treatment alone (NCT01411371)
- 2026-08-03Results posted on the registry: Kanecia Obie Zimmerman, IVIG + Coordinated Care + IVIG Placebo + Coordinated Care (NCT06305780)
- 2026-07-20Phase 3 first posted: National Institute of Cardiovascular Diseases, Pakistan, Ivabradine 5mg Tab + Placebo Oral Tablet (NCT07714746)
- 2025-12-05Phase 3 first posted: Gødstrup Hospital, atenolol + Metoprolol tartrate (NCT07268170)
- 2025-10-30Also stopped (terminated): Tulane University School of Medicine, dronedarone 400 mg Oral Tablet + Placebo (NCT04704050)
- 2025-10-16Results posted on the registry: Tulane University School of Medicine, dronedarone 400 mg Oral Tablet + Placebo (NCT04704050)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision